Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity, Disclosure

Stockholders' Equity, Disclosure

3 Months Ended

Mar. 31, 2017

Notes

Stockholders' Equity, Disclosure

5. STOCKHOLDERS EQUITY:

Stock Options

	Number of Options	Weighted Average Exercise Price	Weighted Average Remaining Life (Years)
Balance, December 31, 2016	269,500	$ 1.88	2.04
Granted	--	$ --	--
Exercised	--	$ --	--
Cancelled	(22,000)	$ 1.64	--
Balance, March 31, 2017	247,500	$ 1.90	1.95
Exercisable, March 31, 2017	247,500	$ 1.90	1.95

The Company recognized no stock-based compensation expense during the three months ended March 31, 2017 and $5,062 during the three months ended March 31, 2016.

As of March 31, 2017 there was no unrecognized compensation expense related to the issuance of the stock options. As of March 31, 2016 there was $1,629 of unrecognized compensation expense related to the issuance of the stock options.

Performance Stock Options

There were no performance stock options granted during the three months ended March 31, 2017 and 2016.

	Number of Options	Weighted Average Exercise Price
Balance, December 31, 2016	40,000	$ 2.00
Granted	--	--
Exercised	--	--
Cancelled	--	--
Balance, March 31, 2017	40,000	$ 2.00
Exercisable, March 31, 2017 and December 31, 2016	40,000	$ 2.00

Warrants

There were no warrants issued during the three months ended March 31, 2017.

	Number of Warrants	Weighted Average Exercise Price	Weighted Average Remaining Life (Years)
Balance, December 31, 2016	2,000,304	$ 2.36	0.63
Granted	--	--	--
Exercised	--	--	--
Cancelled	(333,329)	$ 3.00	--
Balance, March 31, 2017	1,666,975	$ 2.23	0.49